最近批准的治疗方法在与年龄相关的黄斑退化症中的安全性
Ibrahim Khanani1, Aamir A Aziz2, Zoha A Khanani3
1Duke University, Durham, NC.
International ophthalmology clinics
|December 23, 2024
概括
最近的FDA批准为与年龄相关的黄斑变性 (AMD) 提供了新的治疗方法. 本综述检查了新药和新血管AMD和地理缩的设备在临床试验和现实世界的使用中的安全性.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学 是一个学科.
- 医疗器械 医疗器械
背景情况:
- 近年来,在治疗晚年黄斑变性 (AMD) 方面取得了重大进展.
- 多种新药和一种新型药物输送装置已获得FDA批准,用于新血管AMD (nAMD) 和地理缩 (GA).
研究的目的:
- 审查最近FDA批准的nAMD和GA治疗方法的安全性.
- 评估这些新疗法的临床试验和现实世界的安全数据.
主要方法:
- 在过去五年内对FDA批准的nAMD和GA药物的审查.
- 从关键临床试验和现实研究中分析安全数据.
- 包括特定的药物:布罗卢齐祖马布,法里西马布,阿弗利塞普特8毫克,Ranibizumab的港口输送系统,佩格塞塔科普兰和阿瓦辛卡普塔德佩戈尔.
主要成果:
- 针对nAMD的新药包括布罗卢齐祖马布,法里西马布,阿弗利塞普特8毫克和带有拉尼比祖马布的端口输送系统.
- 首批批准用于GA的药物是佩格塞塔科普兰和avacincaptad pegol.
- 临床试验和现实世界的安全性评估对于了解这些新疗法的影响至关重要.
结论:
- 现实世界的数据对于指导新型AMD药物的实施和临床决策至关重要.
- 医生利用现实世界的证据来告知治疗选择,包括剂量和后续计划.
- 持续评估不同患者群体的安全性对于优化AMD管理至关重要.
更多相关视频
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.0K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.0K
相关概念视频
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...